Response to Office communication dated: 05/03/2007

Attorney Docket: UCONAP/141/US

AMENDMENT TO CLAIMS

Please amend the claims as follows:

1-22. cancelled

23. (previously presented) The method of claim 28 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof

$$AA - C - NH - C_2H_5, \quad AA - C - NH \qquad OH \qquad AA - C - O - C_4H_2OH$$

$$AA - C - O - C \qquad OH \qquad AA - C - NH \qquad OH$$

$$AA - C - N \qquad OH \qquad AA - C - NH \qquad OH$$

$$AA - C - N \qquad OH \qquad AA - C - NH \qquad OH$$

$$AA - C - N \qquad OH \qquad AA - C - NH \qquad OH$$

$$AA - C - NH \qquad OH$$

Response to Office communication dated: 05/03/2007

Attorney Docket: UCONAP/141/US

24. (previously presented) The method of claim 28 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

$$AA - C - NH - C_2H_5, \quad AA - C - NH \qquad OH, \quad AA - C - O - C_4H_2OH, \quad OH = AA - C - O - C_4H_2OH, \quad OH = AA - C - NH \qquad OH = AA$$

Response to Office communication dated: 05/03/2007

Attorney Docket: UCONAP/141/US

25. (previously presented) The method of claim 28 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

26. cancelled

27. (previously presented) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a pharmacological preparation comprising a therapeutically effective amount of a compound represented by the following structural formula and physiologically acceptable salts thereof:

Response to Office communication dated: 05/03/2007

Attorney Docket: UCONAP/141/US

28. (currently amended) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a pharmacological preparation comprising a compound represented by the following structural formula and physiologically acceptable salts thereof

AA
$$\longrightarrow C$$
 $\longrightarrow NH$ $\longrightarrow C_2H_5$ AA $\longrightarrow C$ $\longrightarrow NH_2$ AA $\longrightarrow C$ $\longrightarrow OH$ \longrightarrow

Response to Office communication dated: 05/03/2007

Attorney Docket: UCONAP/141/US

29. (currently amended) The method of claim 24 wherein the compound is in

isolated and substantially purified form.

30. (currently amended) The method of claim 24 wherein the pharmacological

preparation further comprises at least one member selected from an excipient, a

vehicle, an adjuvant, a flavoring, a colorant, or a preservative and the compound is in

isolated and substantially purified form.

31. (currently amended) The method of claim 27 wherein the compound is in

isolated and substantially purified form.

32. (currently amended) The method of claim 27 wherein the pharmacological

preparation further comprises at least one member selected from an excipient, a

vehicle, an adjuvant, a flavoring, a colorant, or a preservative and the compound is in

isolated and substantially purified form.

33. (currently amended) The method of claim 28 wherein the compound is in

isolated and substantially purified form.

34. (currently amended) The method of claim 28 wherein the pharmacological

preparation further comprises at least one member selected from an excipient, a

vehicle, an adjuvant, a flavoring, a colorant, or a preservative and the compound is in

isolated and substantially purified form.

6